Bone erosion

VYNE Therapeutics Reports Positive Results from Preclinical Models for Oral BD2-Selective BET Inhibitor VYN202

Retrieved on: 
Monday, October 30, 2023

“These compelling preclinical data in skin inflammation and joint disease models highlight VYN202’s potential for therapeutic utility in both psoriasis and rheumatoid arthritis.

Key Points: 
  • “These compelling preclinical data in skin inflammation and joint disease models highlight VYN202’s potential for therapeutic utility in both psoriasis and rheumatoid arthritis.
  • Treatment was then administered intraperitoneally with either VYN202, deucravacitinib (an allosteric TYK2 inhibitor), or placebo.
  • Each treatment group orally received either placebo, GSK620 (an early generation BD2-selective BET inhibitor) at 10 mg/kg, or VYN202 at three different dose strengths (1, 3, or 10 mg/kg).
  • If successful, VYNE anticipates commencing Phase 1b trials in moderate-to-severe plaque psoriasis and in moderate-to-severe adult-onset rheumatoid arthritis in the second half of 2024.

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) IN PSORIATIC ARTHRITIS AT EULAR 2023

Retrieved on: 
Tuesday, May 30, 2023

THOUSAND OAKS, Calif., May 30, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new research examining the use of Otezla® (apremilast) in psoriatic arthritis, including the Phase 4 MOSAIC study and an exploratory analysis of cardiometabolic risk factors, which are commonly elevated in patients with psoriatic disease. The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), taking place May 31-June 3 in Milan, Italy.

Key Points: 
  • The findings will be presented at the 2023 European Congress of Rheumatology (EULAR), taking place May 31-June 3 in Milan, Italy.
  • "Research presented at EULAR sheds new light on psoriatic arthritis and the role of our oral medication Otezla," said Ponda Motsepe-Ditshego, vice president, Global Medical at Amgen.
  • MOSAIC evaluated Otezla's effect on joint inflammation and structural progression of psoriatic arthritis measured by MRI.
  • "The results of this study are encouraging, as they provide important insights about Otezla treatment and its efficacy on both clinical and inflammatory manifestations of psoriatic arthritis."

MyMD Pharmaceuticals’ Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis

Retrieved on: 
Tuesday, April 12, 2022

Rheumatoid arthritis is a chronic autoimmune disease and an inflammatory form of arthritis.

Key Points: 
  • Rheumatoid arthritis is a chronic autoimmune disease and an inflammatory form of arthritis.
  • Rheumatoid arthritis is the most common form of autoimmune arthritis, affecting more than 1.3 million Americans4 and occuring at any age.
  • Studies have determined that the number of people suffering from rheumatoid arthritis may rise to over 78 million by 20405.
  • Moreover, microscopic changes associated with rheumatoid arthritis (e.g., inflammation, bone erosion, and bone degeneration) are observed in CAIA control animals.

VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis

Retrieved on: 
Wednesday, March 30, 2022

The data demonstrated that VYNEs pan-BET inhibitor VYN201 used as an intra-articular injection resulted in significant inhibition of inflammation in a validated animal model of RA1.

Key Points: 
  • The data demonstrated that VYNEs pan-BET inhibitor VYN201 used as an intra-articular injection resulted in significant inhibition of inflammation in a validated animal model of RA1.
  • Symptoms of RA most commonly include pain, swelling, redness and stiffness in the affected joints, limiting the range of motion2.
  • In addition, the mice received a lipopolysaccharide injection systemically at day 4 to stimulate an acute systemic inflammatory response.
  • For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com or follow VYNE on Twitter.

Scipher Medicine Closes $110 Million Financing

Retrieved on: 
Thursday, February 24, 2022

Scipher Medicine , a precision immunology company matching each patient with their most effective therapy, today announced the completion of a $110 million financing.

Key Points: 
  • Scipher Medicine , a precision immunology company matching each patient with their most effective therapy, today announced the completion of a $110 million financing.
  • To date, Scipher has raised $227 million.
  • Scipher Medicine, a precision immunology company matching patients with their most effective therapy, believes that patients deserve simple answers to treatment options based on scientific data.
  • Visit http://www.sciphermedicine.com and follow Scipher Medicine on Twitter, Facebook, and LinkedIn.

Scipher Medicine Announces Publication of Real-World Study Demonstrating Clinical Utility of PrismRA® Blood Test

Retrieved on: 
Tuesday, February 1, 2022

PrismRA is the only blood test in the market informing personalized treatment decisions for patients with RA.

Key Points: 
  • PrismRA is the only blood test in the market informing personalized treatment decisions for patients with RA.
  • According to the study, patients whose treatment was guided by PrismRA experienced three times better clinical response compared to patients whose therapy selection was not guided by PrismRA results.
  • Study results also suggest that PrismRA has high clinical utility, providing individualized patient information that guided physician therapy selection in 74% of patients.
  • PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.

Nearly 15% of Prescribing U.S. Rheumatologists Use Scipher Medicine’s PrismRA® Blood Test Since Its Launch A Year Ago

Retrieved on: 
Monday, December 6, 2021

PrismRA is the only blood test in the market informing personalized treatment decisions for patients with rheumatoid arthritis (RA).

Key Points: 
  • PrismRA is the only blood test in the market informing personalized treatment decisions for patients with rheumatoid arthritis (RA).
  • PrismRA identifies patients unlikely to respond to TNFi drugs, enabling non-responders to be prescribed alternative FDA-approved therapy from day one that could significantly improve clinical outcomes.
  • Rheumatologists, their patients, and healthcare stakeholders are responding very positively to PrismRA, said Sam Asgarian, M.D., chief medical officer of Scipher Medicine.
  • PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally.

Researchers Present Global Effort to Develop Machine Learning Tools for Automated Assessment of Radiographic Damage in Rheumatoid Arthritis

Retrieved on: 
Saturday, November 6, 2021

This includes both joint space narrowing (which indicates cartilage loss) and bone erosions (which indicates damage from invasion of the inflamed joint lining).

Key Points: 
  • This includes both joint space narrowing (which indicates cartilage loss) and bone erosions (which indicates damage from invasion of the inflamed joint lining).
  • "For example, researchers could analyze data from electronic health records and from genetic and other research assays to find biomarkers associated with progressive damage.
  • Having to score all the images by visual inspection ourselves would be tedious, and outsourcing it is cost prohibitive."
  • Additional sets of images were then provided so the competitors could test and refine the tools they had developed.